FDA Section 4 \u2022 who must NOT take this

Levodopa - Contraindications

These conditions, allergies, and situations mean Levodopa should NOT be used. From the US FDA-approved drug label Section 4.

CONTRAINDICATIONS Nonselective monoamine oxidase (MAO) inhibitors are contraindicated for use with carbidopa and levodopa extended-release tablets.

These inhibitors must be discontinued at least two weeks prior to initiating therapy with carbidopa and levodopa extended-release tablets.

Carbidopa and levodopa extended-release tablets may be administered concomitantly with the manufacturer’s recommended dose of an MAO inhibitor with selectivity for MAO type B (e.g., selegiline hydrochloride) (see PRECAUTIONS: Drug Interactions ).

Carbidopa and levodopa extended-release tablets are contraindicated in patients with known hypersensitivity to any component of this drug, and in patients with narrow-angle glaucoma.

Does any of this apply to YOU?

Ask Health AI \u2192